一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300723 一品红

交易中 06-23 10:15:45

{"stockData":{"symbol":"300723","market":"SZ","secType":"STK","nameCN":"一品红","latestPrice":36.34,"timestamp":1782180945000,"preClose":33.12,"halted":0,"volume":11854287,"delay":0,"changeRate":0.0972,"floatShares":419000000,"shares":451999999,"eps":0.4428,"marketStatus":"交易中","change":3.22,"latestTime":"06-23 10:15:45","open":32.91,"high":36.43,"low":32.91,"amount":417000000,"amplitude":0.1063,"askPrice":36.34,"askSize":7,"bidPrice":36.3,"bidSize":25,"shortable":0,"etf":0,"ttmEps":0.4428,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1782185400000},"marketStatusCode":2,"adr":0,"adjPreClose":33.12,"symbolType":"stock","openAndCloseTimeList":[[1782178200000,1782185400000],[1782190800000,1782198000000]],"highLimit":36.43,"lowLimit":29.81,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":451692766,"isCdr":false,"pbRate":7.73,"roa":"--","peRate":82.068654,"roe":"35.91%","epsLYR":-0.7478,"committee":-0.699812,"marketValue":16415000000,"turnoverRate":0.0283,"status":0,"floatMarketCap":15233000000},"requestUrl":"/m/hq/s/300723/tweets","defaultTab":"tweets","newsList":[{"id":"2645774079","title":"股市必读：一品红（300723）6月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645774079","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645774079?lang=zh_cn&edition=full","pubTime":"2026-06-23 01:08","pubTimestamp":1782148096,"startTime":"0","endTime":"0","summary":"截至2026年6月22日收盘，一品红报收于33.12元，下跌0.9%，换手率2.86%，成交量11.97万手，成交额3.85亿元。公司公告汇总：全资子公司获盐酸丙卡特罗口服溶液《药品注册证书》，注册分类为化学药品3类，视同通过一致性评价，适应症覆盖多种呼吸道阻塞性疾病，批准文号有效期至2031年6月16日。药品批准文号有效期至2031年6月16日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300000622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645078733","title":"一品红（300723）披露全资子公司获得盐酸丙卡特罗口服溶液注册证书的公告，6月22日股价下跌0.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645078733","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645078733?lang=zh_cn&edition=full","pubTime":"2026-06-22 22:17","pubTimestamp":1782137854,"startTime":"0","endTime":"0","summary":"截至2026年6月22日收盘，一品红报收于33.12元，较前一交易日下跌0.9%，最新总市值为149.6亿元。该股当日开盘33.0元，最高33.19元，最低31.37元，成交额达3.85亿元，换手率为2.86%。一品红药业集团股份有限公司近日披露公告，其全资子公司广州一品红制药有限公司收到国家药品监督管理局签发的盐酸丙卡特罗口服溶液《药品注册证书》。药品为处方药，适用于成人及儿童，属国家医保乙类产品。药品批准文号有效期至2031年6月16日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200038851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645502858","title":"一品红：APH03867片与AR882均为URAT1抑制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2645502858","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645502858?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:57","pubTimestamp":1782118633,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红06月22日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司不是有疼风药准备上市了吗，为何还要研发APH03867.两款有什么区别一品红回复：公司申报临床的痛风创新药APH03867片与公司在研的创新药AR882都是口服、非肽类小分子URAT1抑制剂，通过抑制URAT1活性，阻断尿酸在肾小管的重吸收，增加尿酸排泄，从而有效降低血尿酸。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200024132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645042092","title":"一品红(300723.SZ)：子公司获得盐酸丙卡特罗口服溶液注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2645042092","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645042092?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:08","pubTimestamp":1782115688,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)公告，公司全资子公司广州一品红制药有限公司于近日收到国家药品监督管理局核准签发的关于盐酸丙卡特罗口服溶液的《药品注册证书》。该药品用于缓解下述疾病的呼吸道阻塞性障碍引起的呼吸困难等症状：支气管哮喘、慢性支气管炎、急性支气管炎、喘息性支气管炎。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456851.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK4202","300723","CRI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645095063","title":"每周股票复盘：一品红（300723）全资子公司创新药获临床试验受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2645095063","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645095063?lang=zh_cn&edition=full","pubTime":"2026-06-21 02:30","pubTimestamp":1781980229,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总：全资子公司创新药APH03867片获临床试验注册申请受理公司公告汇总关于全资子公司创新药APH03867片获得临床试验注册申请受理的公告一品红药业集团股份有限公司全资子公司广州一品红制药有限公司自主研发的创新药APH03867片的药物临床试验申请已获国家药品监督管理局受理，适应症为痛风伴高尿酸血症。APH03867片为化学药品1类创新药，通过抑制URAT1活性，促进尿酸排泄，降低血尿酸水平。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100000676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","BK0239","06978","159992","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644523771","title":"一品红(300723.SZ)：子公司创新药APH03867片获得临床试验注册申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2644523771","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644523771?lang=zh_cn&edition=full","pubTime":"2026-06-18 12:01","pubTimestamp":1781755286,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)公告，近日，公司全资子公司广州一品红制药有限公司自主研发的创新药物APH03867片的药物临床试验申请获得国家药品监督管理局受理，并收到《受理通知书》。据悉，APH03867片是公司自主研发的一种新型口服、非肽类小分子URAT1(全称：Urate Transporter 1，中文译为：尿酸转运蛋白1)抑制剂，通过抑制肾脏中URAT1的活性，阻断尿酸在肾小管的重吸收，增加尿酸排泄，达到有效降低血尿酸的效果，可用于改善高尿酸血症和痛风症状。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455998.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","300723","06978","BK0239","BK1574","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644872375","title":"股市必读：一品红（300723）6月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2644872375","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644872375?lang=zh_cn&edition=full","pubTime":"2026-06-18 02:05","pubTimestamp":1781719513,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘，一品红报收于32.78元，下跌1.27%，换手率1.76%，成交量7.4万手，成交额2.42亿元。董秘最新回复投资者： 董秘好，公司股价近半年跌近30%，中小投资者损失惨重。交易信息汇总资金流向6月17日主力资金净流出1463.67万元，占总成交额0.0%；游资资金净流出1155.68万元，占总成交额0.0%；散户资金净流入2619.35万元，占总成交额0.0%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800001602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644746792","title":"一品红：2025年12月中旬同意回购公司股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2644746792","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644746792?lang=zh_cn&edition=full","pubTime":"2026-06-17 20:51","pubTimestamp":1781700707,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红06月16日在投资者关系平台上答复投资者关心的问题。2025年12月中旬，公司董事会同意公司以集中竞价方式回购公司部分已发行的人民币普通股（A股）股票用于维护公司价值及股东权益。回购的资金总额为不低于人民币10,000万元且不超过人民币20,000万元。回购价格不超过人民币70.00元/股（含）。截至回购期末，公司累计回购316.22 万股，占公司总股本的 0.70%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700039413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642446677","title":"一品红(300723.SZ)子公司创新药APH03571片获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2642446677","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642446677?lang=zh_cn&edition=full","pubTime":"2026-06-10 15:53","pubTimestamp":1781078020,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布公告，近日，公司全资子公司广州一品红制药有限公司自主研发的创新药物APH03571片的药物临床试验申请已获得国家药品监督管理局批准，并收到《药物临床试验批准通知书》，将于近期开展临床试验。APH03571是公司研制的拟用于携带FLT3(全称：FMS-like tyrosine kinase 3)突变的复发性或难治性急性髓系白血病成人患者的治疗药品。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK0239","BK1574","300723","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642414727","title":"一品红：AR882国内Ⅲ期临床试验完成全部患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2642414727","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642414727?lang=zh_cn&edition=full","pubTime":"2026-06-10 11:30","pubTimestamp":1781062222,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红06月09日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，AR882Ⅲ期目前处于数据锁库还是随访收尾阶段？EULAR大会是否会披露阶段性临床数据？2025年11月，公司在研的痛风创新药AR882国内Ⅲ期临床试验完成全部患者入组。目前，正在进行关键性Ⅲ期临床试验，试验进展顺利。公司将严格按照相关法律法规要求履行信息披露义务。敬请广大投资者谨慎决策，注意投资风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061000016990.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640182158","title":"一品红(300723.SZ)子公司创新药APH04935片获得临床试验注册申请受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2640182158","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640182158?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:12","pubTimestamp":1780560741,"startTime":"0","endTime":"0","summary":"智通财经APP讯，一品红(300723.SZ)发布公告，近日，公司全资子公司广州一品红制药有限公司自主研发的创新药物APH04935片的药物临床试验申请获得国家药品监督管理局受理，并收到《受理通知书》。APH04935片是由公司自主研发的一种高活性、高选择性的小分子GLP-1R激动剂，目标成为一款一天给药一次的口服小分子GLP-1R激动剂，拟用于成人超重或肥胖患者的体重减轻及长期减重管理。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","159992","06978","300723","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640720919","title":"一品红(300723)5月31日股东户数3.6万户，较上期减少14.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640720919","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640720919?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:37","pubTimestamp":1780393041,"startTime":"0","endTime":"0","summary":"证券之星消息，近日一品红披露，截至2026年5月31日公司股东户数为3.6万户，较4月30日减少5967.0户，减幅为14.21%。在化学制药行业个股中，一品红股东户数高于行业平均水平，截至5月31日，化学制药行业平均股东户数为3.56万户。从股价来看，2026年4月30日至2026年5月31日，一品红区间涨幅为5.93%，在此期间股东户数减少5967.0户，减幅为14.21%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200034030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640913423","title":"一品红：截止至2026年5月31日，公司股东总户数36,010户","url":"https://stock-news.laohu8.com/highlight/detail?id=2640913423","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640913423?lang=zh_cn&edition=full","pubTime":"2026-06-02 15:57","pubTimestamp":1780387031,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)06月02日在投资者关系平台上答复投资者关心的问题。投资者提问：现在股东人数一品红回复：尊敬的投资者您好，感谢您对公司的关注。截止至2026年5月31日，公司股东总户数36,010户。祝您投资愉快。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200026929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640965798","title":"股市必读：一品红（300723）6月1日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2640965798","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640965798?lang=zh_cn&edition=full","pubTime":"2026-06-02 01:01","pubTimestamp":1780333277,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，一品红报收于42.4元，下跌3.44%，换手率4.41%，成交量18.49万手，成交额7.94亿元。董秘最新回复投资者： 目前疼风药成功上市，会是治疗疼风石的唯一药品吗？目前，公司股东已收到SOBI公司的投资并购首付款，正在履行必要的程序，公司控股股东将会尽快履行承诺。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200001058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640543639","title":"一品红：控股股东承诺无偿给予Arthrosi股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2640543639","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640543639?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:48","pubTimestamp":1780318097,"startTime":"0","endTime":"0","summary":"公司控股股东广润集团承诺待上述交易完成后，将其子公司 Guangrun Health 持有Arthrosi 的 9.07%股权按照 E 轮投资后的净收益无偿、无条件给予公司，支持公司研发创新发展。目前，公司股东已收到SOBI公司的投资并购首付款，正在履行必要的程序，公司控股股东将会尽快履行承诺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100037905.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638669431","title":"5月28日一品红发生1笔大宗交易 成交金额1410.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2638669431","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638669431?lang=zh_cn&edition=full","pubTime":"2026-05-28 17:27","pubTimestamp":1779960421,"startTime":"0","endTime":"0","summary":"证券之星消息，5月28日一品红发生大宗交易，交易数据如下：大宗交易成交价格40.3元，相对当日收盘价折价0.81%，成交35万股，成交金额1410.5万元，买方营业部为国泰海通证券股份有限公司上海自贸试验区第二分公司，卖方营业部为中国中金财富证券有限公司上海黄浦区中山东二路证券营业部。近三个月该股共发生1笔大宗交易，合计成交3500.0手，折价成交1笔。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800030880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637387542","title":"一品红最新公告：全资子公司获氨基己酸注射液注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2637387542","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637387542?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:40","pubTimestamp":1779360004,"startTime":"0","endTime":"0","summary":"一品红(300723.SZ)公告称，全资子公司广州一品红制药近日收到国家药监局核准签发的氨基己酸注射液《药品注册证书》，该药品为化学药品3类，视同通过一致性评价，用于预防及治疗血纤维蛋白溶解亢进引起的各种出血。2025年该药品在中国城市和县级公立医院销售规模约7388万元。此次获批将进一步丰富公司产品管线，增强核心竞争力。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100036776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637243048","title":"股市必读：一品红（300723）5月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2637243048","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637243048?lang=zh_cn&edition=full","pubTime":"2026-05-21 01:12","pubTimestamp":1779297131,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，一品红报收于38.18元，下跌0.78%，换手率2.27%，成交量9.51万手，成交额3.63亿元。董秘最新回复投资者： 公司是否已经开始组建 AR882 的商业化团队？2025年8月，公司在研的痛风创新药氘泊替诺雷全球Ⅲ期临床试验完成全部受试者入组；2025年11月，AR882国内Ⅲ期临床试验完成全部患者入组。公司将严格按照相关法律法规要求履行信息披露义务。当日关注点来自交易信息汇总：5月20日主力资金净流出3558.94万元，散户资金净流入3737.08万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100001746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636817159","title":"一品红：氘泊替诺雷全球Ⅲ期临床试验完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2636817159","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636817159?lang=zh_cn&edition=full","pubTime":"2026-05-20 17:00","pubTimestamp":1779267637,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红05月20日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问AR882氘泊替诺雷国内三期临床是否按计划6月完成收尾？2025年8月，公司在研的痛风创新药氘泊替诺雷全球Ⅲ期临床试验完成全部受试者入组；2025年11月，AR882国内Ⅲ期临床试验完成全部患者入组。目前，AR882正在进行关键性Ⅲ期临床试验，相关试验开展顺利，产品上市时间可期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000030397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636175108","title":"一品红：公司正在有序规划及准备AR882后续上市后的商业化事宜","url":"https://stock-news.laohu8.com/highlight/detail?id=2636175108","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636175108?lang=zh_cn&edition=full","pubTime":"2026-05-20 16:57","pubTimestamp":1779267434,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)05月20日在投资者关系平台上答复投资者关心的问题。投资者提问：公司是否已经开始组建 AR882 的商业化团队？团队规模和人员构成是怎样的？一品红回复：尊敬的投资者您好，感谢您对公司的关注。公司正在有序规划及准备AR882后续上市后的商业化事宜，公司会制定切实可行的完整的商业化市场方案，在产品上市前逐步调整到位。药品研发具有周期长、投入高、风险大等特点，敬请广大投资者谨慎决策，注意投资风险。祝您投资愉快。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000030299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782180948150,"stockEarnings":[{"period":"1week","weight":-0.0556},{"period":"1month","weight":-0.1934},{"period":"3month","weight":0.0792},{"period":"6month","weight":-0.0507},{"period":"1year","weight":-0.3219},{"period":"ytd","weight":-0.0128}],"compareEarnings":[{"period":"1week","weight":0.0161},{"period":"1month","weight":0.0122},{"period":"3month","weight":0.0726},{"period":"6month","weight":0.0564},{"period":"1year","weight":0.2391},{"period":"ytd","weight":0.0489}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"一品红药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"36010人(较上一季度减少14.21%)","perCapita":"11640股","listingDate":"2017-11-16","address":"广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大厦17层","registeredCapital":"45169万元","survey":"　　一品红药业集团股份有限公司的主营业务是药品研发、生产、销售。公司的主要产品是儿童药产品、慢病药产品。依托完善的创新研发体系，结合多年的市场经验，公司形成了覆盖面广、重点突出、阶梯化储备的产品结构，聚焦于特色儿童药及创新慢病药领域。截至本报告披露之日，公司（含全资及控股子公司）新增技术发明专利5项，目前，公司共有专利125项，其中国内专利114项，境外专利11项；共有商标477项，软件著作权45项。","listedPrice":17.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"一品红,300723,一品红股票,一品红股票老虎,一品红股票老虎国际,一品红行情,一品红股票行情,一品红股价,一品红股市,一品红股票价格,一品红股票交易,一品红股票购买,一品红股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}